LYMEPOLICYWONK: Tee Time for Lyme

Byldoadmin

This graphic is her design.  I think it is great.  I love the slogan:  Lyme isn’t everywhere, but it could be anywhere.  Isn’t that true?  Silver got Lyme in Southern California.  Malibu to be precise.  It’s an endemic area.  Who knew?  Lyme isn’t everywhere, but it could be anywhere.  It’s so true.   

I liked the design and slogan so much I made a tee shirt from it.  No, two.  One for me and one for Silver.  Drop me a comment or email if you think we should print up more!

You can reach Lorraine Johnson, JD, MBA at lbjohnson@lymedisease.org.

Similar Posts

  • LYMEPOLICYWONK: Lyme Healthcare Access and Burden of Illness Survey Results Published!

    In 2009 prior to the IDSA hearing, CALDA wanted patient voices to be heard and conducted a survey that drew over 4,000 responses. It ended up being the largest survey of Lyme patients ever conducted in the United States. Today, the results of this survey were published in Health Policy in a study by Johnson, Aylward and Stricker. Health Policy is a highly regarded peer-reviewed journal that explores health policy issues. This survey focused on 2,424 respondents whose clinical diagnosis was supported by positive test results. The study examines problems with access to healthcare and burden of illness, and it found that although patients with Lyme disease suffered a substantial burden of illness, they had significant barriers to healthcare access. Specifically, patients with Lyme disease had difficulty obtaining diagnosis and treatment for their illness, traveled great distances to receive healthcare, were turned down for health insurance based on their illness, and had difficulty receiving care at local hospitals.

  • LYMEPOLICYWONK: Uncle Sam Needs Patients to Get Healthcare Reform Right

    Recently, a group that writes guidelines asked for my input about the role of patients in the development of Evidence Based Medicine guidelines. With universal healthcare now ‘the law of the land’, treatment guidelines have become even more important. Preserving the integrity of the guideline development- process is what matters most. It is essential that patients play a role in the process that can so affect their lives. The question posed to me was why should those developing guidelines involve patients? My response follows.

  • LYMEPOLICYWONK: A Question of Ethical Reporting–Chicago Tribune/Los Angeles Times.

    Biased reporting harms the credibility of journalism, harms patients, and misleads the public. The recent Tribune piece, which is now being republished in other Tribune outlets (including the Los Angeles Times) distorts and manipulates reality and makes a ‘good story’ at the expense of professional journalism. It does this by ignoring science, and by characterizing patients as hapless victims and their physicians as frauds. It was called to task for its profound lack of professionalism by Knight Science Journalism Tracker. Articles on science that do not present both sides of a legitimate controversy in science do a serious injustice and may violate the canons of journalist ethics established by the Society of Professional Journalism. Today, I look at some of those canons and point out how the Tribune article fell short. More after the jump. . .

  • Bias and patient autonomy—what’s the connection

    Everyone is entitled to their own opinion. So why do we care about bias in medical guidelines? Because opinion should not dictate patient care. Think of the prostate cancer patient who sees the surgeon who recommends surgery, the radiologist who recommends radiation treatment, and the internist who recommends watchful waiting. Everyone knows that one’s position depends on where one sits. The surgeon may genuinely prefer surgery and when he recommends it to his patient, the patient realizes that he is, after all, talking with a surgeon and that surgeons are likely to favor surgery. He also knows that he can walk down the street a bit and talk with the radiologist and get his perspective. The point is that even though the patient is given conflicting advice, at the end of the day the decision is his. He chooses among treatment options and the physicians respect his decision. This is called autonomy—a recognition that patients are entitled to make choices among health care options.

  • IDSA HEARING: Follow the hearing and comment 8 a.m.-5 p.m. ET, July 30

    We are providing blog updates of testimony throughout the day.
    We will post frequent updates of the hearing testimony starting at 8 a.m. Eastern time. You can add comments at the bottom of this page. However, you must hit the refresh button on your browser periodically, so that you can see new postings and comments as they are added. If you keep this page open without refreshing it, you won’t see any of the updates.

  • LYMEPOLICYWONK: When is Mandatory, Mandatory? When Medco says so!

    I have gotten a lot of reports from patients that Medco is refusing to dispense antibiotics because of the IDSA guidelines. At $51 Billion, let me repeat that $51 BILLION, dollar in revenue, Medco is the nation’s largest drug dispensing company. And, just for the record, they are over-riding the treatment recommendation of the treating physician and replacing it with, oh yeah, the IDSA “expert opinions” on treatment. This isn’t evidence based medicine, this is “eminence based medicine.” Their mission is to help “clients control the cost and enhance the quality” of prescription benefits. Looks like the IDSA is their friend. Complaints about Medco using these tactics have been becoming more frequent suggesting that this is not an isolated case and may be an across the board policy? If so, its reliance on IDSA guidelines to deny treatment across the board will have a serious adverse impact on patient lives.